Navigation Links
Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
Date:6/13/2013

BOULDER, Colo., June 13, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference in Boston.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Wells Fargo Securities Research and Economics 2013 Healthcare ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Wednesday, June 19, 2013Time:9:15 a.m. Eastern Time Location:InterContinental Hotel,  Boston, MAWebcast:www.arraybiopharma.comAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
2. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
3. Array BioPharma Announces Proposed Public Offering of Convertible Debt
4. Two Array Invented MEK Inhibitors Showcased At ASCO
5. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
6. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
9. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
10. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... WA (PRWEB) , ... May ... ... a full service insurance provider serving families of Camas and Vancouver, WA, ... current campaign fundraises for the National Breast Cancer Foundation and their Mammography ...
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces an ... DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses tested ... at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising new ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , ā€œIā€™m excited for our eighth summer here in San Diego,ā€ says ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Dr. ... offering wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental ... not always problematic, they often are improperly erupted, resulting in risks of complications. By ...
Breaking Medicine News(10 mins):